InflaRx N.V. (IFRX) Increases to $48.59

InflaRx N.V. (NASDAQ:IFRX) rose significantly to $48.59. Barchart.com posted it on Apr, 13. It has $1.26 billion MC. $50.48M more could be NASDAQ:IFRX valuation at $50.53 share price.

For more InflaRx N.V. (NASDAQ:IFRX) news published briefly go to: Seekingalpha.com, Globenewswire.com, Globenewswire.com, Globenewswire.com or Globenewswire.com. The titles are as follows: “InflaRx down 14% – Seeking Alpha” published on November 19, 2018, “InflaRx Opens New Research Facility in Ann Arbor – GlobeNewswire” on June 05, 2018, “InflaRx Continues U.S. Expansion with Addition of New York City Corporate Office and Addition of Management – GlobeNewswire” with a publish date: January 03, 2019, “InflaRx N.V. Announces Appointment of Jens Holstein to Board of Directors – GlobeNewswire” and the last “InflaRx N.V. To Host R&D Day on Hidradenitis Suppurativa and its Breakthrough Anti-C5a Monoclonal Antibody IFX-1 – GlobeNewswire” with publication date: August 28, 2018.

InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States.The firm is valued at $1.26 billion. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases.Last it reported negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.

InflaRx N.V. (NASDAQ:IFRX) Analyst Ratings Chart


Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.


Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *